{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:47:43Z","timestamp":1781736463070,"version":"3.54.5"},"reference-count":30,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Reports"],"abstract":"<jats:p>Mucormycosis is a life-threatening disease requiring multimodal treatment with antifungals and surgery. The mortality rate remains high, prompting consideration of alternative treatment strategies. Deferiprone has in vitro activity against Mucorales, but its efficacy has never been evaluated in humans. Here, we retrospectively analyzed patients with confirmed mucormycosis who received deferiprone from 2011 to 2017. Five patients had hematologic malignancies and one was diabetic. The sites of infection included sinus-orbit-cerebral (67%), lung (17%), and disseminated infection (17%). Surgery was performed in 83% of cases and achieved local control for 33% of patients. A combination regimen of polyenes plus echinocandins was administered with stepdown treatment using posaconazole. The median duration of antifungal treatment was 86 days (range: 46-435 days) days. Deferiprone was given as adjunctive treatment with a median dose and duration of 100 mg\/kd\/day (range: 86.2-100 mg\/kg\/day) and 25 days (range: 15-215 days), respectively. Overall, deferiprone was well-tolerated. Successful outcomes were observed at 12-week follow-up for 67% of patients. The mortality rate at 180- day follow-up was 50%. Adjunctive therapy with deferiprone showed safety and tolerability.<\/jats:p>","DOI":"10.4081\/idr.2018.7765","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T09:36:43Z","timestamp":1539077803000},"page":"7765","source":"Crossref","is-referenced-by-count":12,"title":["Deferiprone as Adjunctive Treatment for Patients with Invasive Mucormycosis: A Retrospective Case Series"],"prefix":"10.3390","volume":"10","author":[{"given":"Maria N.","family":"Chitasombat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimjai","family":"Niparuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12879-016-2023-z","article-title":"Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study","volume":"16","author":"Kontoyiannis","year":"2016","journal-title":"BMC Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0002-9629(15)40691-3","article-title":"Transfusion iron overload in adults with acute leukemia: manifestations and therapy","volume":"319","author":"Barton","year":"2000","journal-title":"Am J Med Sci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/myc.12232","article-title":"Host-iron assimilation: pathogenesis and novel therapies of mucormycosis","volume":"57","author":"Ibrahim","year":"2014","journal-title":"Mycoses"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jac\/dkl350","article-title":"Deferiprone iron chelation as a novel therapy for experimental mucormycosis","volume":"58","author":"Ibrahim","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1172\/JCI32338","article-title":"The iron chelator deferasirox protects mice from mucormycosis through iron starvation","volume":"117","author":"Ibrahim","year":"2007","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1128\/AAC.00792-10","article-title":"Activity of deferasirox in Mucorales: influences of species and exogenous iron","volume":"55","author":"Lewis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1128\/AAC.01065-06","article-title":"Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis","volume":"50","author":"Reed","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1128\/AAC.00361-09","article-title":"Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis","volume":"53","author":"Spellberg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The deferasirox-ambisome therapy for mucormycosis (DEFEAT Mucor) study: a randomized, doubleblinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11908-010-0129-9","article-title":"Recent advances in the treatment of mucormycosis","volume":"12","author":"Spellberg","year":"2010","journal-title":"Curr Infect Dis Rep"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/13693780903311944","article-title":"Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases","volume":"48","author":"Shoham","year":"2010","journal-title":"Med Mycol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eimc.2010.09.008","article-title":"Mortality risk factors in patients with zygomycosis: a retrospective and multicentre study of 25 cases","volume":"29","author":"Llorente","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jac\/dkr529","article-title":"Deferasirox in mucormycosis: hopefully, not defeated","volume":"67","author":"Soman","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/jac\/dkr540","article-title":"Deferasirox as adjunctive therapy for mucormycosis","volume":"67","author":"Donnelly","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000087888","article-title":"Safety and effectiveness of 100 mg\/kg\/day deferiprone in patients with thalassemia major: a two-year study","volume":"114","author":"Taher","year":"2005","journal-title":"Acta Haematol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17474086.2017.1318052","article-title":"Deferiprone for the treatment of transfusional iron overload in thalassemia","volume":"10","author":"Belmont","year":"2017","journal-title":"Exp Rev Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1128\/CMR.00056-10","article-title":"Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species","volume":"24","author":"Gomes","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/jac\/dkv198","article-title":"Invasive mould sinusitis in patients with haematological malignancies: a 10 year single-centre study","volume":"70","author":"Davoudi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dkq437","article-title":"Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients","volume":"66","author":"Pagano","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cmi.2016.01.005","article-title":"Mucormycosis in Australia: contemporary epidemiology and outcomes","volume":"22","author":"Kennedy","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/1469-0691.12408","article-title":"Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival","volume":"20","author":"Vironneau","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"ref29","first-page":"811","article-title":"Initial use of combination treatment does not impact early survival of 106 patients with hematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Mycoses"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/idr\/article\/download\/7765\/7453","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/idr\/article\/download\/7765\/7471","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2036-7449\/10\/2\/7765\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T03:55:48Z","timestamp":1644465348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/10\/2\/7765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["idr.2018.7765"],"URL":"https:\/\/doi.org\/10.4081\/idr.2018.7765","relation":{},"ISSN":["2036-7449"],"issn-type":[{"value":"2036-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,25]]}}}